Diane Raccasi

FDA investigator

Appears on 5 documents from 2015 to 2019, most often at sites in California. Most often cites general requirements (21 CFR 211.160).

5
Documents on file
5.6
Observations per 483
2015
First seen
2019
Most recent

What they cite most

From 28 observations

Activity by year

2015: 1, 2017: 2, 2018: 1, 2019: 1

Where

California 1 · India 1 · New York 1 · South Korea 1 · Texas 1

Is Diane Raccasi coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

5 documents, newest first
FirmOpen
483 Biocon LimitedFeb 15, 2019 · Bangalore, India
483 Samsung Biologics Co., Ltd.May 11, 2018 · Incheon, South Korea
483 Boehringer Ingelheim Fremont, Inc.Apr 4, 2017 · Fremont, California
483 Wyeth Pharmaceutical Division of Wyeth Holdings LLCMar 17, 2017 · Pearl River, New York
483 Allergan Sales, LLCOct 8, 2015 · Waco, Texas

About this profile

What does Diane Raccasi inspect?

Diane Raccasi appears on 5 documents on file covering 5 sites, most often in California.

What do they cite most often?

21 CFR 211.160 (general requirements), followed by 21 CFR 211.113 and 21 CFR 211.22.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Diane Raccasi is dated Feb 15, 2019.